1 completed, 1 terminated, 1 withdrawn. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow thrombomodulin alfa: new trials by email Literature Review of thrombomodulin alfa trials Research Report on thrombomodulin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients thrombomodulin alfa, Placebo - Chemotherapy-induced Peripheral Neuropathy | Phase 1 | Terminated | Veloxis Pharmaceuticals | 77 | 2022-03-24 | 2024-08-19 |
| A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo thrombomodulin alfa, Placebo - Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Withdrawn | Veloxis Pharmaceuticals | 2021-10-01 | 2022-02-18 | |
| Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy ART-123, Placebo - Severe Sepsis, Coagulopathy | Phase 3 | Completed | Asahi Kasei Pharma America Corporation | 816 | 2012-10-29 | 2020-04-21 |
Hemostatic Disorders (1) · Sepsis (1)
Veloxis Pharmaceuticals (2) · Asahi Kasei Pharma America Corporation (1)
United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Israel (1)
David Fineberg, M.D. (1) · David Fineberg, MD (1) · Libbie McKenzie, MD FASN (1)